Regulation of B-cell receptor signaling and its therapeutic relevance in aggressive B-cell lymphomas
Simple Summary Dysregulated B-cell receptor (BCR) signaling is considered a potent
contributor to tumor survival in different subtypes of B-cell non-Hodgkin lymphomas (B …
contributor to tumor survival in different subtypes of B-cell non-Hodgkin lymphomas (B …
Targeting PI 3‐kinase (PI 3 K), AKT and m TOR axis in lymphoma
JS Blachly, RA Baiocchi - British journal of haematology, 2014 - Wiley Online Library
Targeted therapy represents a transformation in oncology, a field that has relied primarily on
non‐selective cytotoxic therapies. Phosphatidylinositol 3‐kinase (PI 3 K) is a family of …
non‐selective cytotoxic therapies. Phosphatidylinositol 3‐kinase (PI 3 K) is a family of …
Imidazopyridazine compounds and their use
W Su, G Dai, W Zhang, W Deng - US Patent 10,208,066, 2019 - Google Patents
This disclosure provides novel imidazopyridazine com pounds of formula (I) and
pharmaceutical acceptable salt thereof, pharmaceutical compositions containing them, a …
pharmaceutical acceptable salt thereof, pharmaceutical compositions containing them, a …
Novel pharmacotherapies for B-cell lymphomas and leukemias
MT Tees, L Sokol - American Journal of Therapeutics, 2016 - journals.lww.com
Novel pharmacotherapeutic agents were recently approved for treatment of low-grade B-cell
neoplasms, and many other agents are under investigation. Several agents have …
neoplasms, and many other agents are under investigation. Several agents have …
Compounds for reducing c-Myc in c-Myc overexpressing cancers background
C Deng, M Lipstein, O O'connor, DW Landry… - US Patent …, 2021 - Google Patents
The invention relates to new compounds that reduce c-Myc expression and useful for cancer
treatment, particularly hematological cancers such as aggressive B-and T-cell lymphomas …
treatment, particularly hematological cancers such as aggressive B-and T-cell lymphomas …
Imidazopyridazine compounds and their use
W Su, G Dai, W Zhang, W Deng - US Patent 10,611,777, 2020 - Google Patents
Int. Cl. C07D 487/04(2006.01) A61P 19/02(2006.01) A61P 35/00(2006.01) C07D
519/00(2006.01) A61P 11/00(2006.01) A61P 29/00(2006.01) A61P 37/00(2006.01)(52) US …
519/00(2006.01) A61P 11/00(2006.01) A61P 29/00(2006.01) A61P 37/00(2006.01)(52) US …
TARGETING CASEIN KINASE-1 AND PI3K/AKT/mTOR PATHWAYS FOR TREATMENT OF C-MYC-OVEREXPRESSING CANCERS, ORGAN TRANSPLANT …
D Changchun, SX Deng, DW Landry, M LIPSTEIN… - 2017 - Google Patents
WO2017079558A1 - TARGETING CASEIN KINASE-1 AND PI3K/AKT/mTOR PATHWAYS FOR
TREATMENT OF C-MYC-OVEREXPRESSING CANCERS, ORGAN TRANSPLANT ASSOCIATED …
TREATMENT OF C-MYC-OVEREXPRESSING CANCERS, ORGAN TRANSPLANT ASSOCIATED …